Opportunities Preloader

Please Wait.....

Report

Oncology Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology), Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging), Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy), Applied Sciences (Genomics, Pharmacogenomics, Others), Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others), By Application (Solid Tumor v/s Hematological Malignancies), Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others), Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others), and By Region

Market Report I 2022-11-01 I 111 Pages I TechSci Research

The global oncology precision medicine market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. Precision medicine represent the medical approach for the prevention of disease and diagnosis which is based on genetic, environmental, and behavioural variability. It helps in illnesses susceptibility prediction, diseases diagnosis, and progression, as well as medicine prescription. It assists in taking healthcare related decisions, improving quality care, and declining inefficiencies due to the trial-and-error is also augmenting the market growth. Precision medicine is widely utilized to diagnose the chromosomal abnormalities in the foetus and cancer and works for therapy for chronic diseases. The escalating demand of oncology precision medicine methods owing to the growing prevalence of cancer and the expanding number of treatment candidates in clinical trials are fueling the growth of the market.
Increasing Risk of Chronic Diseases in Geriatric Population Drives the Market Growth
Most cancer diagnoses occur in adults over the age of 65 years which demands the accurate treatment plan for this age group. Several oncologists use recommended and available geriatric assessments to help in evaluating older patients and guide their cancer treatment planning. The concept of precision medicine extends beyond tumour-specific markers to incorporate host factors that are assessed as part of a routine geriatric assessment. Oncologists are always careful to stage the cancer in creating cancer treatment plans by giving the importance of staging the aging to ensure that cancer treatments are personalized to as per the patient condition. Assessing the health status of older adults is as important and essential to optimizing treatment as assessing tumour biology and should be included alongside other precision medicine initiatives. I applaud the authors on a well-written and insightful article on implementing geriatric assessment and encourage oncology providers to use geriatric assessments in the routine care of their older patients and to apply this knowledge to individualize their care of this growing and vulnerable population.
Rise in Use of Targeted Gene Therapy is Expected to Propel the Market Growth
Gene therapy considered as one of the most lucrative markets for precision medicine organizations. Genome sequencing is an unavoidable stage of gene therapy, the extensive investments that are being made in this field drives the growth of the precision medicine market. The increase in number of cancers is escalating the demand for gene therapy as an effective personalized treatment choice across the globe. The significant growth in the number of patients necessitates gene therapy as a potential treatment approach addressing the increasing global burden of the disease. With this, the expanding adoption of emerging genomic technologies, including NGS and high-density microarray, along with the several government initiatives is propelling the market growth.
Market Segmentation
The global oncology precision medicine market is segmented into ecosystem, application, and regional distribution. Based on the ecosystem, the market is divided into precision diagnostics, precision therapeutics, applied sciences, digital health, and information technology. Based on the precision diagnostics, the market is bifurcated into molecular diagnostics and medical imaging. Based on the precision therapeutics, the market is divided into clinical trials, cell therapy, drug discovery & research, gene therapy. Based on the applied sciences, the market is divided into genomics, pharmacogenomics, others. Based on the digital health, and information technology, the market is divided into clinical decision support systems (CDSS), big data analytics, genomics informatics, in-silico informatics, others. Based on application, the market is segmented into insect scouting, crop disease scouting, weed scouting, others. Based on application, the market is bifurcated into solid tumor and hematological malignancies. Based on solid tumor, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, others. Based on hematological malignancies, the market is divided into hodgkin lymphoma, non-hodgkin lymphoma, leukemia, others. The market analysis also studies the regional segmentation, divided among North American region, Asia-Pacific region, European region, South American region, and Middle East & African region.
Market Players
Novartis AG, F. Hoffmann-La Roche AG, Merck & Co., Inc., Danaher Corporation, Abbott Laboratories, Inc., Quest Diagnostics Inc, Eurofins Genomics LLC, Laboratory Corporation of America Holdings, Thermos Fischer Scientific, Inc., bioMerieux SA are the leading market players contributing the growth of the global oncology precision medicine market.
Report Scope:
In this report, global oncology precision medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Oncology Precision Medicine Market, By Ecosystem:
o Precision Diagnostics
o Precision Therapeutics
o Applied Sciences
o Digital Health
o Information Technology
- Oncology Precision Medicine Market, By Precision Diagnostics:
o Molecular Diagnostics
o Medical Imaging
- Oncology Precision Medicine Market, By Precision Therapeutics:
o Clinical Trials
o Cell Therapy
o Drug Discovery & Research
o Gene Therapy
- Oncology Precision Medicine Market, By Applied Sciences:
o Genomics
o Pharmacogenomics
o Others
- Oncology Precision Medicine Digital Health, and Information Technology:
o Clinical Decision Support Systems (CDSS)
o Big Data Analytics
o Genomics Informatics
o In-Silico Informatics
o Others
- Oncology Precision Medicine Market, By Application:
o Solid Tumor
o Hematological Malignancies
- Oncology Precision Medicine Market, By Solid Tumor:
o Breast Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Others
- Oncology Precision Medicine Market, By Hematological Malignancies:
o Hodgkin Lymphoma
o Non-Hodgkin Lymphoma
o Leukemia
o Others
- Oncology Precision Medicine Market, By Region:
o North America
- United States
- Canada
- Mexico
o Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Singapore
- Malaysia
o Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Poland
- Denmark
o South America
- Brazil
- Argentina
- Colombia
- Peru
- Chile
o Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Iraq
- Turkey
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global oncology precision medicine market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).

1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Oncology Precision Medicine Market
5. Voice of Customer
5.1. Oncology Precision Medicine Awareness
5.2. Cancer Prevalence, By Gender
5.3. Cancer Prevalence, By Age Group
5.4. Cancer Prevalence, Region
5.5. Benefits of Using Precision Medicine in Oncology
6. Clinical Trial Analysis
7. Patent Analysis
8. Global Oncology Precision Medicine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
8.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
8.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
8.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
8.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
8.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
8.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
8.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
8.2.3. By Region
8.2.4. By Company (2021)
8.3. Product Market Map
9. North America Oncology Precision Medicine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
9.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
9.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
9.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
9.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
9.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
9.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
9.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
9.2.3. By Country
9.3. North America: Country Analysis
9.3.1. United States Oncology Precision Medicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Ecosystem
9.3.1.2.2. By Application
9.3.2. Mexico Oncology Precision Medicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Ecosystem
9.3.2.2.2. By Application
9.3.3. Canada Oncology Precision Medicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Ecosystem
9.3.3.2.2. By Application
10. Europe Oncology Precision Medicine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
10.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
10.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
10.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
10.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
10.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
10.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
10.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
10.2.3. By Country
10.3. Europe: Country Analysis
10.3.1. France Oncology Precision Medicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Ecosystem
10.3.1.2.2. By Application
10.3.2. Germany Oncology Precision Medicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Ecosystem
10.3.2.2.2. By Application
10.3.3. United Kingdom Oncology Precision Medicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Ecosystem
10.3.3.2.2. By Application
10.3.4. Italy Oncology Precision Medicine Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Ecosystem
10.3.4.2.2. By Application
10.3.5. Spain Oncology Precision Medicine Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Ecosystem
10.3.5.2.2. By Application
11. Asia-Pacific Oncology Precision Medicine Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
11.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
11.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
11.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
11.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
11.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
11.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
11.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
11.2.3. By Country
11.3. Asia-Pacific: Country Analysis
11.3.1. China Oncology Precision Medicine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Ecosystem
11.3.1.2.2. By Application
11.3.2. India Oncology Precision Medicine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Ecosystem
11.3.2.2.2. By Application
11.3.3. South Korea Oncology Precision Medicine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Ecosystem
11.3.3.2.2. By Application
11.3.4. Japan Oncology Precision Medicine Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Ecosystem
11.3.4.2.2. By Application
11.3.5. Australia Oncology Precision Medicine Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Ecosystem
11.3.5.2.2. By Application
12. South America Oncology Precision Medicine Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
12.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
12.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
12.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
12.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
12.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
12.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
12.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
12.2.3. By Country
12.3. South America: Country Analysis
12.3.1. Brazil Oncology Precision Medicine Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Ecosystem
12.3.1.2.2. By Application
12.3.2. Argentina Oncology Precision Medicine Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Ecosystem
12.3.2.2.2. By Application
12.3.3. Colombia Oncology Precision Medicine Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Ecosystem
12.3.3.2.2. By Application
13. Middle East and Africa Oncology Precision Medicine Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
13.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
13.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
13.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
13.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
13.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
13.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
13.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
13.2.3. By Country
13.3. MEA: Country Analysis
13.3.1. South Africa Oncology Precision Medicine Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1. By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1. By Ecosystem
13.3.1.2.2. By Application
13.3.2. Saudi Arabia Oncology Precision Medicine Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1. By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1. By Ecosystem
13.3.2.2.2. By Application
13.3.3. UAE Oncology Precision Medicine Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1. By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1. By Ecosystem
13.3.3.2.2. By Application
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
16. SWOT Analysis: Global Oncology Precision Medicine Market
17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)
17.1. Novartis AG
17.2. F. Hoffmann-La Roche AG
17.3. Merck & Co., Inc.
17.4. Danaher Corporation
17.5. Abbott Laboratories, Inc.
17.6. Quest Diagnostics Inc
17.7. Eurofins Genomics LLC
17.8. Laboratory Corporation of America Holdings
17.9. Thermos Fischer Scientific, Inc.
17.10. bioMerieux SA
18. Strategic Recommendations

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE